What is US Patent 6596746 for Dasatinib?
U.S. Patent 6,596,746 covers dasatinib, a drug used to treat certain types of leukemia [1]. The patent was filed by Bristol-Myers Squibb.
When Does the Dasatinib Patent Expire?
The primary U.S. patent for dasatinib, US 6,596,746, expired in July 2020. However, other patents related to formulations and methods of use may extend market exclusivity for specific applications [2]. DrugPatentWatch.com provides detailed information on patent expiry dates and other intellectual property for dasatinib [1].
Who Makes Dasatinib?
Bristol-Myers Squibb originally developed and markets dasatinib under the brand name Sprycel [3].
What is Dasatinib Used For?
Dasatinib is a tyrosine kinase inhibitor approved for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) [1][3].
How Does Dasatinib Work?
Dasatinib functions by inhibiting multiple tyrosine kinases, including BCR-ABL, SRC-family kinases, c-KIT, EPHA2, and PDGFR-beta [3]. This inhibition disrupts the signaling pathways that drive cancer cell growth in certain leukemias.
What Are the Risks or Side Effects of Dasatinib?
Common side effects of dasatinib include diarrhea, headache, rash, fatigue, nausea, muscle pain, abdominal pain, bleeding, and bone pain [3]. More serious side effects can include fluid retention, bone marrow suppression, and heart problems [3].
Can Generic Versions of Dasatinib Be Made After Patent Expiry?
Following the expiration of key patents, generic manufacturers can seek approval from regulatory agencies like the FDA to produce and market generic dasatinib [2]. This typically involves demonstrating bioequivalence to the branded product.
What Are Other Treatments for CML and ALL?
Other treatments for CML and ALL include other tyrosine kinase inhibitors like imatinib (Gleevec), nilotinib (Tasigna), and bosutinib (Bosulif), as well as chemotherapy and stem cell transplantation, depending on the specific diagnosis and stage of the disease [4].
What is the Difference Between Sprycel and Generic Dasatinib?
Sprycel is the brand-name version of dasatinib. Generic dasatinib contains the same active ingredient and is expected to have the same therapeutic effect. The primary differences may lie in inactive ingredients, appearance, and cost.
What is the Pricing of Dasatinib?
Pricing for dasatinib, particularly brand-name Sprycel, can be substantial. Generic versions, once available, are typically expected to be less expensive, though actual costs can vary by manufacturer, pharmacy, and insurance coverage [5].
Are There Any Ongoing Patent Disputes for Dasatinib?
Patent litigation is common in the pharmaceutical industry, especially around the time of patent expiry. Specific details on ongoing disputes related to dasatinib patents can be complex and may involve challenges to patent validity or inventorship [2]. DrugPatentWatch.com can offer insights into such litigation [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fiercepharma.com/
[3] https://www.cancer.gov/
[4] https://www.lls.org/
[5] https://www.goodrx.com/